Le Lézard
Classified in: Health
Subject: SVY

Global Demand for Parenteral Containers to Grow 7.7% Annually Through 2023

CLEVELAND, Jan. 21, 2020 /PRNewswire/ -- Parenteral containers will generate favorable growth opportunities in both developed and developing countries. The developed economies of the United States, Canada, Western Europe, Japan, and South Korea will account for 61% of 2023 demand, reflecting the broad range of injectable medication produced by advanced pharmaceutical industries. These and other trends are included in Global Pharmaceutical Packaging, a study from The Freedonia Group. 

Freedonia Group logo

Demand in the rest of the world will remain more limited based on the lower volume and less diverse mix of parenteral drug production. However, overall growth in the developing countries will expand at a fast pace as pharmaceutical makers gradually broaden lines of injectable therapies.

Global demand for parenteral containers is forecast to increase 7.7% annually to $19.5 billion in 2023, representing 97.8 billion units. Gains will be divided among prefillable syringes, vials and ampuls, and IV containers and will follow trends in the development and production of injectable medicines. Through 2023, parenteral containers will post one of the fastest gains in demand value among all pharmaceutical packaging segments.

Contact Corinne Gangloff for an interview with the analyst.

Additional Packaging studies can be viewed here:

About The Freedonia Group ? The Freedonia Group, a division of MarketResearch.com, is a leading international industrial research company publishing more than 100 studies annually. Since 1985 we have provided research to customers ranging in size from global conglomerates to one-person consulting firms. More than 90% of the industrial companies in the Fortune 500 use Freedonia Group research to help with their strategic planning. Each study includes product and market analyses and forecasts, in-depth discussions of important industry trends, and market share information. Studies can be purchased at www.freedoniagroup.com and are also available on www.marketresearch.com and www.profound.com.

Press Contact:
Corinne Gangloff
+1 440.842.2400


SOURCE The Freedonia Group

These press releases may also interest you

19 sep 2020
The food safety warning issued on August 11, 2020 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Sunsprout Natural...

19 sep 2020
The office of Kenneth R. Russell DDS is always open to investing in new technologies to provide better patient care and ensure positive outcomes. Recently, Dr. Russell invested in the highly effective BIOLASE Epictm and Waterlasetm technologies,...

19 sep 2020
A flying armada organized by volunteer pilots flying private aircraft today delivered 100,000 KN95 respirators from Direct Relief's California-based humanitarian distribution center to residents and firefighters in Oregon's worst-hit fire-zones....

19 sep 2020
Results from a prespecified exploratory analysis of the positive ADAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a clinically meaningful improvement in central nervous system (CNS) disease-free survival (DFS) in the...

19 sep 2020
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb's Opdivo® (nivolumab)...

19 sep 2020
Bristol Myers Squibb and Exelixis, Inc. today announced the first presentation of results from the pivotal Phase 3 CheckMate -9ER trial, in which Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) demonstrated significant...

News published on 21 january 2020 at 09:37 and distributed by: